Access & reimbursement resources
Your privacy is important to us
We want to be transparent about the data we and our partners collect and how we use it. We and our partners use 1st and 3rd party cookies (or similar) in order to enhance your overall web browsing experience, measure our audience, collect useful information to allow us and our partners to provide you with ads tailored to your interests, and permit you to share content on social media. Some cookies can be deactivated by clicking on the “Decline” button below. You may modify your choices at any time by using the “Privacy settings” link on our website. For more information, please see our Privacy Notice.
Cookies used by our partners
Testing the category description for testing purposes
STUDY DESIGN
| ECOSPOR III |
|---|
|
Multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in adults (≥18 years) with recurrent C. diff 1-3 |
|
Primary Endpoint
Secondary Endpoints
|
Recurrence confirmed with C. diff toxin test and ≥3 unformed bowel movements per day over 2 days*
|
|
10–21 days of vancomycin (125 mg QID) or fidaxomicin (200 mg BID)
|
ECOSPOR III efficacy endpoints based on intent-to-treat population.
Data were rounded to the nearest whole number for presentation.
STUDY DESIGN
ECOSPOR IV was an open-label, single arm study of 263 participants with ≥1 C. diff recurrences evaluating the safety of VOWST; the secondary endpoint was efficacy5
Limitations: open-label study design yields descriptive results limiting interpretations of efficacy and safety without a comparator
| ECOSPOR IV |
|---|
|
Multicenter, open-label, single-arm trial in adults (≥18 years) with recurrent C. diff 5 |
|
Primary Endpoint
Secondary Endpoints
|
|
Recurrence confirmed with
C. diff
toxin test
or
PCR
and ≥3 unformed bowel movements per day over 2 days*
|
|
10–42 days of vancomycin
or 10–25 days of fidaxomicin |
Toxin and PCR testing were utilized to determine initial eligibility. Recurrences while on study were confirmed by toxin testing to ensure study integrity.
†25 placebo recipients and 4 VOWST recipients discontinued ECOSPOR III and enrolled in ECOSPOR IV after experiencing a C. Diff recurrence within 8 weeks.
Data were rounded to the nearest whole number for presentation.